VACCINEX INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
VCNX$1.41-61.4%Stored close · as of Dec 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets (Unaudited)
(in thousands, except share and per share data)
| As of March 31, 2024 | As of December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $2,972 | $1,535 |
| Accounts receivable | 2,775 | 961 |
| Prepaid expenses and other current assets | 1,312 | 853 |
| Derivative asset | 95 | - |
| Total current assets | 7,154 | 3,349 |
| Property and equipment, net | 110 | 136 |
| Operating lease right-of-use asset | 103 | 146 |
| TOTAL ASSETS | $7,367 | $3,631 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,329 | $2,039 |
| Accrued expenses | 1,880 | 1,242 |
| Deferred revenue | 59 | 63 |
| Current portion of long-term debt | 76 | 75 |
| Operating lease liability | 103 | 146 |
| Warrant liability | 259 | 2,351 |
| Total current liabilities | 4,706 | 5,916 |
| Long-term debt | 6 | 26 |
| TOTAL LIABILITIES | 4,712 | 5,942 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity (deficit): | ||
| Convertible preferred stock (Series A), par value of $0.001 per share; 10,000,000 shares authorized, 10 shares issued and outstanding as of March 31, 2024, and no shares authorized, issued or outstanding as of December 31, 2023; with aggregate liquidation preference of $1,750,000 and $0 as of March 31, 2024 and December 31, 2023, respectively | 1,236 | - |
| Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2024, and December 31, 2023; 1,584,305 and 892,622 shares issued as of March 31, 2024 and December 31, 2023, respectively; 1,584,300 and 892,617 shares outstanding as of March 31, 2024 and December 31, 2023, respectively | 1 | - |
| Additional paid-in capital | 345,253 | 337,627 |
| Treasury stock, at cost; 5 shares of common stock as of March 31, 2024, and December 31, 2023, respectively | (11) | (11) |
| Accumulated deficit | (343,824) | (339,927) |
| TOTAL STOCKHOLDERS’ EQUITY/(DEFICIT) | 2,655 | (2,311) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $7,367 | $3,631 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.